Institute for Information Industry (III) Partners with Skymizer to Advance Taiwan-Built On-Premise AI Solutions

Institute for Information Industry (III) Partners with Skymizer to Advance Taiwan-Built On-Premise AI Solutions

From Edge AI to Enterprise On-Premise AI — Skymizer HTX301, the world's first on-premise AI inference chip, powered by HyperThought IP and scaling from Edge to On-Premise to Mini Data Center TAIPEI, May 27, 2026 /PRNewswire/ -- The Institute for...

BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints

BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints

SUZHOU, China, May 5, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as " BrightGene Bio-Medical" or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent...

Haier Biomedical Hosts European Partner Summit in Rome and Advances "In Europe, for Europe" Strategy

Haier Biomedical Hosts European Partner Summit in Rome and Advances "In Europe, for Europe" Strategy

ROME, March 11, 2026 /PRNewswire/ -- Haier Biomedical recently convened its European Partner Summit in Rome under the theme "Advancing Together - Sharing the Future of Biomedical Innovation," which brought together 37 regional partners and industry...

Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC

Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC

CHENGDU, China, Oct. 17, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab botidotin...

menu
menu